4.8 Article

Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement

期刊

CELL
卷 186, 期 21, 页码 4528-+

出版社

CELL PRESS
DOI: 10.1016/j.cell.2023.09.009

关键词

-

向作者/读者索取更多资源

MLL/KMT2A amplifications and rearrangements in leukemia are regulated by the balance of histone H3 lysine 9 mono- and di-methylation (H3K9me1/2) at the MLL/KMT2A locus. This balance is controlled by the interaction between lysine demethylase KDM3B and methyltransferase G9a/EHMT2. This study provides insights into the molecular mechanisms of MLL/KMT2A alterations and identifies potential drug targets for therapeutic intervention.
MLL/KMT2A amplifications and translocations are prevalent in infant, adult, and therapy-induced leukemia. However, the molecular contributor(s) to these alterations are unclear. Here, we demonstrate that histone H3 lysine 9 mono-and di-methylation (H3K9me1/2) balance at the MLL/KMT2A locus regulates these amplifications and rearrangements. This balance is controlled by the crosstalk between lysine demethylase KDM3B and methyltransferase G9a/EHMT2. KDM3B depletion increases H3K9me1/2 levels and reduces CTCF occupancy at the MLL/KMT2A locus, in turn promoting amplification and rearrangements. Depleting CTCF is also sufficient to generate these focal alterations. Furthermore, the chemotherapy doxorubicin (Dox), which associates with therapy-induced leukemia and promotes MLL/KMT2A amplifications and rearrangements, suppresses KDM3B and CTCF protein levels. KDM3B and CTCF overexpression rescues Dox-induced MLL/ KMT2A alterations. G9a inhibition in human cells or mice also suppresses MLL/KMT2A events accompanying Dox treatment. Therefore, MLL/KMT2A amplifications and rearrangements are controlled by epigenetic regulators that are tractable drug targets, which has clinical implications.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据